Challenger rejects TAL's revised offer

Resumen detallado
Challenger has rejected TAL Daiichi Life's revised takeover bid at an improved price valuing the retirement product provider at $8.2 billion.
Challenger has rejected TAL Daiichi Life's revised takeover bid at an improved price valuing the retirement product provider at $8.2 billion.
The new offer price of $12.20 per share is a 40 cents jump from its earlier offer valuing the firm at $7.8 billion.
TAL is Challenger's largest shareholder and is proposing to acquire the remaining 79.5% stake it does not already own.
"The Challenger board has carefully considered the terms of the revised offer including obtaining advice from its financial and legal adviser," Challenger said.
"The board believes that the revised offer does not adequately represent fair value for Challenger shareholders in the context of a control transaction.
"Challenger shareholders do not need to take any action in relation to the revised offer."
At its recent annual general meeting, Challenger said it will continue to engage with TAL for a better offer price.
"TAL Daiichi Life is Challenger's largest shareholder and an important commercial partner, and we value that relationship," Challenger chair Duncan West said.
"Accordingly, the board finds it appropriate to engage with TAL Daiichi Life to determine whether a proposal can be reached that could be recommended to shareholders."
Inicio del artículo, extracto de Financial Standard. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.financialstandard.com.au)




